Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis-Reference-Cited by-同舟云学术

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

Published:2021-01-09 Issue:5 Volume:60 Page:649-654
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

de Rouw Nikki^ORCID,Boosman Rene J.,Huitema Alwin D. R.,Hilbrands Luuk B.,Svensson Elin M.,Derijks Hieronymus J.,van den Heuvel Michel M.,Burger David M.,ter Heine Rob

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-020-00972-1.pdf

Reference24 articles.

1. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S, Committee EG. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192–237.

2. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, Committee EG. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v31–9.

3. Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v40–55.

4. Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44(5):372–80.

5. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24(4):552–62.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study;2024-08-09

2. Sarcopenia as a Predictive Factor for Carboplatin Toxicity in Patients with Advanced Non-Small Cell Lung Cancer;Nutrition and Cancer;2024-07-26

3. Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administration‐induced nephropathy;British Journal of Clinical Pharmacology;2023-08-07

4. Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial;Cancer Chemotherapy and Pharmacology;2022-11-21

5. Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof‐of‐concept study;British Journal of Clinical Pharmacology;2022-09-21